Oxytocin
OXT Β· Pitocin Β· Syntocinon
Endogenous nonapeptide produced in the hypothalamus with well-characterised roles in social bonding, sexual arousal, trust, and uterine contractility. Intranasal delivery bypasses the blood-brain barrier and produces central effects within 30β45 minutes.
Want a personalised protocol?
Our AI generator builds a protocol tailored to your profile and goals.
Mechanism of Action
Acts on oxytocin receptors (OXTR) widely distributed in limbic structures, hypothalamus, and reward circuits. Enhances dopaminergic reward signalling, reduces amygdala fear response, promotes prosocial behaviour, and facilitates sexual arousal in both sexes. Peripheral effects include uterine/smooth muscle contraction and lactation facilitation.
Clinical Applications
- βFemale and male hypoactive sexual desire disorder (HSDD)
- βIntimacy and bonding facilitation in relationship distress
- βSocial anxiety and autism spectrum social cognition (off-label)
- βPost-traumatic stress β reduction of fear consolidation
- βPostpartum bonding support
Dosing Protocol
Recommended Dosing
Intranasal: 24 IU (4 puffs of 6 IU each) administered 15β45 min before desired effect. For therapeutic use: 24 IU 2β3x/week. Onset ~30 min, duration 90β120 min. IV/IM forms are obstetric use only.Safety & Contraindications
Possible Side Effects
- β Mild headache (transient, common on first use)
- β Nasal irritation from spray vehicle
- β Possible emotional sensitisation β some users report increased emotional reactivity
- β Rare: nausea at high doses
Contraindications
- βPregnancy (peripheral OXT causes uterine contractions β intranasal is lower risk but use cautiously)
- βSevere cardiovascular disease (peripheral vasodilation at high doses)
- βSchizophrenia or active psychosis (may amplify social salience dysregulation)